Crinetics Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRNX research report →
Companywww.crinetics.com
Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
- CEO
- R. Scott Struthers
- IPO
- 2018
- Employees
- 437
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $3.82B
- P/E
- -7.61
- P/S
- 211.65
- P/B
- 2.95
- EV/EBITDA
- -6.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.89%
- Op Margin
- -3020.32%
- Net Margin
- -2747.18%
- ROE
- -43.96%
- ROIC
- -40.83%
Growth & Income
- Revenue
- $7.70M · 640.71%
- Net Income
- $-465,317,000 · -55.93%
- EPS
- $-4.95 · -34.15%
- Op Income
- $-516,769,000
- FCF YoY
- -66.95%
Performance & Tape
- 52W High
- $57.99
- 52W Low
- $25.83
- 50D MA
- $37.85
- 200D MA
- $41.17
- Beta
- 0.28
- Avg Volume
- 1.22M
Get TickerSpark's AI analysis on CRNX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 8, 26 | Knight Jeff E. | other | 19,336 |
| Apr 8, 26 | Knight Jeff E. | other | 9,624 |
| Apr 8, 26 | Knight Jeff E. | other | 49,474 |
| Apr 8, 26 | Knight Jeff E. | sell | 85,163 |
| Apr 8, 26 | Knight Jeff E. | other | 19,336 |
| Apr 8, 26 | Knight Jeff E. | other | 49,474 |
| Apr 8, 26 | Knight Jeff E. | other | 9,624 |
| Mar 16, 26 | Knight Jeff E. | sell | 5,950 |
| Mar 16, 26 | Knight Jeff E. | sell | 3,961 |
| Mar 16, 26 | Betz Stephen F. | sell | 6,371 |
Our CRNX Coverage
We haven't published any research on CRNX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRNX Report →